This year may mark some Big (and not so big) Pharma breakthroughs in the area of HIV therapies: good news for the 65,000 AIDS patients in the U.S. who are infected with drug-resistant forms of the virus. This brief spot took a quick look at what Merck, Pfizer, and Gilead are up to.
Bloomberg - (BLOOM)
Feb. 15, 2007. 07:53 AM EST